A clinical study demonstrated that high-dose propofol administration significantly alleviated symptoms of treatment-resistant depression in patients.[7] Furthermore, a recent animal study indicated that propofol rapidly reverses anhedonia associated with chronic stress by directly inhibiting the dopamine transporter and activating D1-type medium spiny neurons (D1-MSNs) in the nucleus accumbens.[8] Propofol is a typical single-agent, multi-target drug that exhibits multi-site, multi-target, and multi-mechanism properties. This evidence concerns the gene SLC6A3 and major depressive disorder.